Clicky

Verona Pharma plc(VRNA)

Description: Verona Pharma plc, a clinical stage biopharmaceutical company, researches, discovers, and develops therapeutic drugs to treat respiratory diseases primarily in the United Kingdom and North America. The company’s lead product is RPL554, an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, which is in Phase IIa clinical trial that acts as a bronchodilator and an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease, cystic fibrosis, and asthma. Verona Pharma plc is based in London, the United Kingdom.


Keywords: Asthma Enzymes Respiratory Diseases Respiratory Therapy Chronic Obstructive Pulmonary Disease Pulmonary Disease Cystic Fibrosis Lactams Pulmonology Treatment Of Chronic Obstructive Pulmonary Disease Chronic Lower Respiratory Diseases Phosphodiesterase Ureas Bronchodilator

Home Page: www.veronapharma.com

VRNA Technical Analysis

3 More London Riverside
London, SE1 2RE
United Kingdom
Phone: 44 20 3283 4200


Officers

Name Title
Dr. David S. Zaccardelli Pres, CEO & Exec. Director
Mr. Mark W. Hahn Chief Financial Officer
Dr. Kathleen A. Rickard Chief Medical Officer
Ms. Claire Louise Poll L.C.S.W., B.A., B Juris, LLB, ASIA Gen. Counsel
Ms. Victoria Stewart Director of Communications
Mr. Matthew Casbon VP of Sales, Marketing & Training
Ms. Ostra Jewell Sr. VP of HR
Dr. Peter Spargo Sr. VP of Chemistry Manufacturing & Controls
Dr. Tara Rheault M.P.H., Ph.D. Sr. VP of R&D
Ms. Nina Church Exec. Director of Global Clinical Devel.

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 4.1364
Price-to-Sales TTM: 18.5606
IPO Date: 2017-04-27
Fiscal Year End: December
Full Time Employees: 24
Back to stocks